Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record.

Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial

Open access
Clive, Amelia O, Taylor, Hazel, Dobson, Lee, Wilson, Paula, de Winton, Emma, Panakis, Niki, Pepperell, Justin, Howell, Timothy, Stewart, Samuel A, Penz, Erika, Jordan, Nikki, Morley, Anna J, Zahan-Evans, Natalie, Smith, Sarah, Batchelor, Timothy J P, Marchbank, Adrian, Bishop, Lesley, Ionescu, Alina A, Bayne, Mike, Cooper, Samantha, Kerry, Anthony, Jenkins, Peter, Toy, Elizabeth, Vigneswaran, Vallipuram, Gildersleve, James, Ahmed, Merina, McDonald, Fiona, Button, Mick, Lewanski, Conrad, Comins, Charles, Dakshinamoorthy, Muthukumar, Lee, Y C Gary, Rahman, Najib M, Maskell, Nick A · 2016 · The Lancet Oncology

Abstract

BACKGROUND: The use of prophylactic radiotherapy to prevent procedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical practice varies worldwide. We aimed to compare prophylactic radiotherapy with deferred radiotherapy (given only when a PTM developed) in a suitably powered trial. METHODS: We did a multicentre, open-label, phase 3, randomised controlled trial in 22 UK hospitals of patients with histocytologically proven mesothelioma who had undergone large-bore pleural interventions in the 35 days prior to recruitment. Eligible patients were randomised (1:1), using a computer-generated sequence, to receive immediate radiotherapy (21 Gy in three fractions within 42 days of the pleural intervention) or deferred radiotherapy (same dose given within 35 days of PTM diagnosis). Randomisation was minimised by histological subtype, surgical versus non-surgical procedure, and pleural procedure (indwelling pleural catheter vs other). The primary outcome was the incidence of PTM within 7 cm of the site of pleural intervention within 12 months from randomisation, assessed in the intention-to-treat population. This trial is registered with ISRCTN, number ISRCTN72767336. FINDINGS: Between Dec 23, 2011, and Aug 4, 2014, we randomised 203 patients to receive immediate radiotherapy (n=102) or deferred radiotherapy (n=101). The patients were well matched at baseline. No significant difference was seen in PTM incidence in the immediate and deferred radiotherapy groups (nine [9%] vs 16 [16%]; odds ratio 0·51 [95% CI 0·19-1·32]; p=0·14). The only serious adverse event related to a PTM or radiotherapy was development of a painful PTM within the radiotherapy field that required hospital admission for symptom control in one patient who received immediate radiotherapy. Common adverse events of immediate radiotherapy were skin toxicity (grade 1 in 50 [54%] and grade 2 in four [4%] of 92 patients vs grade 1 in three [60%] and grade 2 in two [40%] of five patients in the deferred radiotherapy group who received radiotherapy for a PTM) and tiredness or lethargy (36 [39%] in the immediate radiotherapy group vs two [40%] in the deferred radiotherapy group) within 3 months of receiving radiotherapy. INTERPRETATION: Routine use of prophylactic radiotherapy in all patients with mesothelioma after large-bore thoracic interventions is not justified. FUNDING: Research for Patient Benefit Programme from the UK National Institute for Health Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30095-x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 166

Metadata

Authors
Clive, A. O., Taylor, H., Dobson, L., Wilson, P., de Winton, E., Panakis, N., Pepperell, J., Howell, T., Stewart, S. A., Penz, E., Jordan, N., Morley, A. J., Zahan-Evans, N., Smith, S., Batchelor, T. J. P., Marchbank, A., Bishop, L., Ionescu, A. A., Bayne, M., Cooper, S., Kerry, A., Jenkins, P., Toy, E., Vigneswaran, V., Gildersleve, J., Ahmed, M., McDonald, F., Button, M., Lewanski, C., Comins, C., Dakshinamoorthy, M., Lee, Y. C. G., Rahman, N. M., & Maskell, N. A.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2016-08
Volume
17
Issue
8
Pages
1094-1104
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2462276505
Cited by
166
References
0
FWCI
20.66
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30095-x
The paper
Clive, A. O., Taylor, H., Dobson, L., Wilson, P., de Winton, E., Panakis, N., Pepperell, J., Howell, T., Stewart, S. A., Penz, E., Jordan, N., Morley, A. J., Zahan-Evans, N., Smith, S., Batchelor, T. J. P., Marchbank, A., Bishop, L., Ionescu, A. A., Bayne, M., . . . Maskell, N. A. (2016). Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30095-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.